Methods for the treatment of cachexia and graft v. host disease

Details Methods for the treatment of cachexia and graft v. host disease Methods for the treatment of cachexia and graft v. host disease

2005-11-17

2009-12-08

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07629360

ABSTRACT:
Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal.

REFERENCES:
patent: 4590189 (1986-05-01), Hiraga et al.
patent: 4808402 (1989-02-01), Leibovich et al.
patent: 4849441 (1989-07-01), Okazaki et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5463063 (1995-10-01), Muller
patent: 5502066 (1996-03-01), Heinemann et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5605914 (1997-02-01), Muller
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5658940 (1997-08-01), Muller et al.
patent: 5698579 (1997-12-01), Muller
patent: 5703098 (1997-12-01), Muller et al.
patent: 5712291 (1998-01-01), D'Amato
patent: 5728845 (1998-03-01), Muller et al.
patent: 5736570 (1998-04-01), Muller et al.
patent: 5798368 (1998-08-01), Muller et al.
patent: 5801195 (1998-09-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 5968945 (1999-10-01), Muller et al.
patent: 6011050 (2000-01-01), Muller et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6046221 (2000-04-01), Muller et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6124322 (2000-09-01), Bjoerkman et al.
patent: 6228879 (2001-05-01), Green et al.
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6380239 (2002-04-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6476052 (2002-11-01), Muller et al.
patent: 6500845 (2002-12-01), Boehlke et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 6673828 (2004-01-01), Green et al.
patent: 2001/0056114 (2001-12-01), D'Amato
patent: 2002/0045643 (2002-04-01), Muller et al.
patent: 2002/0052398 (2002-05-01), D'Amato
patent: 2002/0054899 (2002-05-01), Zeldis
patent: 2002/0061923 (2002-05-01), D'Amato
patent: 2002/0161023 (2002-10-01), D'Amato
patent: 2002/0173658 (2002-11-01), Muller et al.
patent: 2002/0183360 (2002-12-01), Muller et al.
patent: 2003/0028028 (2003-02-01), Man et al.
patent: 2003/0045552 (2003-03-01), Robarge et al.
patent: 2003/0069428 (2003-04-01), Muller et al.
patent: 2003/0096841 (2003-05-01), Robarge et al.
patent: 2003/0139451 (2003-07-01), Shah et al.
patent: 2003/0144325 (2003-07-01), Muller et al.
patent: 2003/0181428 (2003-09-01), Green et al.
patent: 2003/0187024 (2003-10-01), D'Amato
patent: 2003/0191098 (2003-10-01), D'Amato
patent: 2003/0235909 (2003-12-01), Hariri et al.
patent: 2004/0029832 (2004-02-01), Zeldis
patent: 2004/0077686 (2004-04-01), Dannenberg et al.
patent: 2004/0087546 (2004-05-01), Zeldis
patent: 2004/0091455 (2004-05-01), Zeldis
patent: 2004/0122052 (2004-06-01), Muller et al.
patent: 2004/0127545 (2004-07-01), D'Amato et al.
patent: 2004/0147558 (2004-07-01), Treston et al.
patent: 0 688 771 (1995-12-01), None
patent: WO 92/14455 (1992-09-01), None
patent: WO 94/ 20085 (1994-09-01), None
patent: WO 95/01348 (1995-01-01), None
patent: WO 98/03502 (1998-01-01), None
patent: WO 98/54170 (1998-12-01), None
patent: WO 02/059106 (2002-08-01), None
patent: WO 02/064083 (2002-08-01), None
patent: WO 03/086373 (2003-10-01), None
Luzzio et al. “Thalidomide analogues . . . ” EXp. Opinion ther. Patents, v.1492) p. 215-229 (2004).
Yeh et al. “Geriatric cachexia . . . ” Am. J. Clin. Nutr. v. 70, p. 183-197 (1999).
Gordon et al. “Thalidomide in the treatment . . .” Gut v.54, p. 540-545 (2004).
Kamoshida et al. “Expression of cancer . . .” Biomed. Res. v.27, p. 275-281 (2006).
U.S. Appl. No. 09/287,377, filed Apr. 7, 1999, D'Amato.
U.S. Appl. No. 09/545,654, filed Apr. 10, 2000, D'Amato.
I Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed. 1995).
Bundgaard, “Design of Prodrugs,” Elsevier, pp. 24-25 (1985).
Corral, L. et al., “Immunomodulation by thalidomide and thalidomide analogues”, Annals of the Rheumatic Diseases, vol. 58, Suppl. 1, pp. 1107-1113, 1999.
De et al., “Possible Antineoplastic Agents,”Indian J. Chem., 16B: 510-512 (1978).
De et al., “Hansch analysis for some antineoplastic glutarimides,”J. Indian Chem. Soc. I.III: 825-826 (1976).
De et al., “Possible antineoplastic agents I”,Jour. Pharm. Sci., 64(2): 262-266 (1975).
De et al., “Possible antineoplastic agents II”,J. Pharmaceutical Sciences, 66(2): 232-235 (1977).
De et al., “Possible antineoplastic agents: III. Synthesis of 6-alkyl-2-[4'-methoxyphthalimido] and 6-alky1-3-[3'-4'- dimethoxyphenyl] glutarimides,”J. Indian Chem. Soc. I.III: 1122-1125 (1976).
De et al., “Possible antineoplastic agents: part IV— synthesis & antineoplastic potency of N-substituted a-(4,5- dimethoxyphthalimido)glutarimides & B-(4-bromophenyl)glutarimides,”Indian Jour. Chem. 16B: 510-512 (1978).
He et al., “Synthesis of Thalidomide Analogs and Their Biological Potential for Treatment of Graft versus Host Disease,”J. Am. Chem. Soc. 216 (1993).
Jonsson, “Chemical Structure and Teratogenic Properties,”Acta Pharm. Suecica, 9: 521-542 (1972).
Miyachi, H. et al., Novel Biological Response Modifiers: Phthalimides with Tumor Necrosis Factor- Production-Regulating Activity, J. Med. Chem., pp. 2858-2865 (1997).
Muller, George et al., Amino-Substituted Thalidomide Analogs: Potent Inhibitors of TNF- Production, Bioorganic & Medicinal Chem. Letters 9, pp. 1625-1630 (1999).
Muller, George et al., Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity, Journal of Medicinal Chemistry, vol. 39, No. 17, pp. 3238-3240(1996).
Muller, George et al., Thalidomide Analogs and PDE4 Inhibition, Bioorganic & Medicinal Chemistry Letters 8, pp. 2669- 2674 (1998).
Shannon, Edward J. et al., Immunomodulatory Assays to Study Structure-Activity Relationships of Thalidomide, Immunopharmacology 35, pp. 203-212 (1997).
Smith, R. L. et al., Studies on the Relationship Between the Chemical Structure and Embryotoxic Activity of Thalidomide and Related Compounds, Symp. Embryopathic Act. Drugs, pp. 194-209 (1965).
Takeuchi, Yoshio et al., (R)- and (S)-3-Fluorothalidomides: Isosteric Analogues of Thalidomide, American Chemical Society, vol. 1, No. 10, pp. 1571-1573 (1999).
Udagawa, Taturo et al., Thalidomide and Analogs, Antianglogenia Agents in Cancer Therapy, pp. 263-274. (1999).
Zwingenberger, K. et al., Immunomodulation by Thalidomide: Systematic Review of the Literature and of Unpublished Observations, Journal of Inflammation, pp. 177-211 (1996).
Niwayama et al.,J. Med. Chem. 39 (16):3044-45, 1996.
Schmahl et al.Arch. Toxicol. 70 (11):749-756, 1996.
Wnendt et al.Chirality8(5):390-396, 1996.

Affiliated with

Also associated with

Rating

Methods for the treatment of cachexia and graft v. host disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for the treatment of cachexia and graft v. host disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of cachexia and graft v. host disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4080073